CTMX
CytomX Therapeutics, Inc. NASDAQ Listed Oct 8, 2015$4.00
After hrs
$3.94
-0.91%
Mkt Cap $681.0M
52w Low $0.91
42.3% of range
52w High $8.21
50d MA $4.65
200d MA $3.87
P/E (TTM)
-27.9x
EV/EBITDA
-31.8x
P/B
5.8x
Debt/Equity
0.0x
ROE
-17.5%
P/FCF
-7.8x
RSI (14)
—
ATR (14)
—
Beta
2.48
50d MA
$4.65
200d MA
$3.87
Avg Volume
6.9M
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
151 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.14 | -0.10 | +28.6% | — | — | — | — | — | — | — | — |
| Mar 16, 2026 | AMC | -0.08 | -0.22 | -175.0% | 6.75 | +2.5% | -19.3% | -34.8% | -29.2% | -34.1% | -33.9% | — |
| Nov 6, 2025 | AMC | -0.05 | -0.09 | -82.5% | 4.19 | -9.3% | -13.6% | +0.0% | -2.1% | +1.0% | -7.9% | — |
| Aug 7, 2025 | AMC | -0.06 | -0.00 | +98.0% | 2.10 | -2.4% | +11.9% | +10.0% | -11.4% | -15.2% | -16.2% | — |
| May 12, 2025 | AMC | 0.12 | 0.27 | +116.3% | 2.13 | +1.9% | +17.4% | +11.7% | -6.1% | -4.7% | +0.0% | — |
| Mar 6, 2025 | AMC | -0.23 | 0.22 | +195.7% | 0.62 | +15.0% | +7.7% | +8.5% | +0.5% | -3.0% | -4.3% | — |
| Nov 7, 2024 | AMC | -0.17 | 0.07 | +141.2% | 1.00 | +15.0% | +9.0% | +4.0% | +4.0% | +1.0% | +0.0% | — |
| Aug 8, 2024 | AMC | -0.14 | -0.08 | +42.9% | 1.18 | +0.8% | +1.7% | +0.8% | -1.7% | -1.7% | +0.8% | — |
| May 8, 2024 | AMC | -0.08 | 0.17 | +312.5% | 4.19 | -35.1% | -51.3% | -52.7% | -54.9% | -53.7% | -53.2% | — |
| Mar 11, 2024 | AMC | 0.00 | 0.01 | +133.8% | 2.51 | -19.5% | -14.3% | -16.3% | -17.9% | -17.5% | -19.5% | — |
| Nov 7, 2023 | AMC | -0.19 | 0.04 | +121.1% | 1.28 | +0.8% | -2.3% | -6.2% | -8.6% | -3.9% | +0.0% | — |
| Aug 8, 2023 | AMC | -0.20 | -0.02 | +90.0% | 1.69 | +0.0% | -3.6% | +1.2% | -0.6% | -3.0% | -5.9% | — |
| May 9, 2023 | AMC | -0.11 | -0.05 | +54.9% | 1.72 | +3.5% | +5.8% | +2.9% | +3.5% | +5.8% | +2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.45 | $4.48 | +0.7% | +0.2% | -4.7% | -5.2% | -0.7% | +1.6% |
| Mar 19 | Barclays | Maintains | Overweight → Overweight | — | $4.40 | $4.51 | +2.5% | +8.6% | +1.1% | +1.4% | -3.6% | -4.1% |
| Mar 18 | Guggenheim | Maintains | Buy → Buy | — | $5.45 | $5.27 | -3.3% | -19.3% | -12.3% | -18.3% | -18.2% | -22.2% |
| Mar 18 | Jefferies | Maintains | Buy → Buy | — | $5.45 | $5.27 | -3.3% | -19.3% | -12.3% | -18.3% | -18.2% | -22.2% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $6.75 | $6.92 | +2.5% | -19.3% | -34.8% | -29.2% | -34.1% | -33.9% |
| Mar 16 | JP Morgan | Upgrade | Neutral → Overweight | — | $4.68 | $6.92 | +47.9% | +44.2% | +16.5% | -6.0% | +2.1% | -4.9% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $6.92 | +47.9% | +44.2% | +16.5% | -6.0% | +2.1% | -4.9% |
| Mar 9 | Guggenheim | Maintains | Buy → Buy | — | $4.68 | $4.61 | -1.5% | +7.5% | +4.3% | +4.3% | +4.1% | +0.0% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $6.07 | $6.19 | +2.0% | -6.6% | -13.7% | -6.6% | -6.1% | -8.9% |
| Feb 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.07 | $6.19 | +2.0% | -6.6% | -13.7% | -6.6% | -6.1% | -8.9% |
| Jan 20 | Barclays | Maintains | Overweight → Overweight | — | $5.39 | $5.46 | +1.3% | -0.4% | -1.9% | +6.1% | +2.8% | -0.9% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.39 | $5.46 | +1.3% | -0.4% | -1.9% | +6.1% | +2.8% | -0.9% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.19 | $4.19 | +0.0% | -2.1% | +1.0% | -7.9% | -7.4% | -15.3% |
| Oct 21 | Barclays | Maintains | Overweight → Overweight | — | $3.74 | $3.90 | +4.3% | -3.2% | -9.4% | -11.8% | -12.8% | -10.2% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.14 | +0.5% | -3.3% | -4.2% | +0.0% | +4.7% | +0.0% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.38 | $2.50 | +5.0% | -16.0% | -14.7% | -10.5% | -13.4% | -14.3% |
| May 15 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.38 | $2.50 | +5.0% | -16.0% | -14.7% | -10.5% | -13.4% | -14.3% |
| Apr 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.53 | $0.55 | +3.3% | +13.8% | +18.6% | +18.3% | +23.2% | +40.8% |
| Mar 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.62 | $0.71 | +15.0% | +7.7% | +8.5% | +0.5% | -3.0% | -4.3% |
| Jan 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.14 | $1.15 | +0.9% | -10.5% | -13.8% | -22.8% | -22.2% | -26.2% |
| May 28 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.75 | $1.92 | +9.7% | +2.3% | +0.0% | +0.0% | -2.9% | +0.0% |
| May 9 | Wedbush | Upgrade | Neutral → Outperform | — | $4.19 | $2.72 | -35.1% | -51.3% | -52.7% | -54.9% | -53.7% | -53.2% |
| May 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $4.19 | $2.72 | -35.1% | -51.3% | -52.7% | -54.9% | -53.7% | -53.2% |
| May 6 | Jefferies | Upgrade | Hold → Buy | — | $4.43 | $4.89 | +10.4% | -1.4% | -8.1% | -5.4% | -54.0% | -55.3% |
| May 1 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.63 | $3.25 | +99.4% | +214.7% | +176.1% | +171.8% | +168.1% | +149.7% |
| Apr 22 | JP Morgan | Upgrade | Underweight → Neutral | — | $1.67 | $1.76 | +5.4% | +0.0% | +0.6% | -2.4% | -4.2% | -4.8% |
| Mar 12 | BMO Capital | Maintains | Market Perform → Market Perform | — | $2.51 | $2.02 | -19.5% | -14.3% | -16.3% | -17.9% | -17.5% | -19.5% |
| Mar 12 | Wedbush | Maintains | Neutral → Neutral | — | $2.51 | $2.02 | -19.5% | -14.3% | -16.3% | -17.9% | -17.5% | -19.5% |
| Nov 9 | Wedbush | Maintains | Neutral → Neutral | — | $1.25 | $1.25 | +0.0% | -4.0% | -6.4% | -1.6% | +2.4% | +3.2% |
| Nov 8 | Wedbush | Upgrade | Neutral → Outperform | — | $1.28 | $1.29 | +0.8% | -2.3% | -6.2% | -8.6% | -3.9% | +0.0% |
| Aug 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.69 | $1.69 | +0.0% | -3.6% | +1.2% | -0.6% | -3.0% | -5.9% |
| Mar 28 | Mizuho | Maintains | Neutral → Neutral | — | $1.79 | $1.48 | -17.3% | -15.1% | -14.2% | -17.3% | -15.6% | -14.0% |
| Jan 6 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.79 | $2.96 | +65.4% | +40.8% | +60.9% | +55.3% | +53.1% | +52.5% |
| Nov 14 | BMO Capital | Downgrade | Outperform → Market Perform | — | $1.29 | $1.25 | -3.1% | -1.6% | -7.8% | -6.2% | +24.0% | +34.9% |
| Nov 10 | JP Morgan | Downgrade | Overweight → Underweight | — | $1.24 | $1.19 | -4.0% | +1.6% | +4.0% | +2.4% | -4.0% | -2.4% |
| Jul 11 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $1.30 | $1.28 | -1.5% | -1.5% | -1.5% | +0.0% | +7.7% | +15.4% |
| Jul 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.30 | $1.28 | -1.5% | -1.5% | -1.5% | +0.0% | +7.7% | +15.4% |
| Jul 7 | BMO Capital | Maintains | Outperform → Outperform | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | Jefferies | Downgrade | Buy → Hold | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | Barclays | Maintains | Overweight → Overweight | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | BTIG | Maintains | Buy → Buy | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | Mizuho | Downgrade | Buy → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | Piper Sandler | Downgrade | Overweight → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jul 7 | Wedbush | Downgrade | Outperform → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | -34.0% | -35.0% | -35.0% | -34.0% |
| Jun 24 | BMO Capital | Maintains | Outperform → Outperform | — | $1.87 | $1.95 | +4.3% | +1.6% | +3.7% | -0.5% | +0.0% | -2.1% |
| Mar 2 | JP Morgan | Maintains | Overweight → Overweight | — | $3.54 | $3.89 | +9.9% | +14.1% | +7.9% | +4.8% | +6.2% | +7.6% |
| Jan 18 | Barclays | Upgrade | Underweight → Overweight | — | $3.95 | $4.18 | +5.8% | -3.0% | +3.3% | +5.3% | +8.6% | +11.1% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.87 | $3.81 | -1.6% | +4.7% | +9.0% | +9.3% | +12.1% | +15.5% |
| Nov 15 | BTIG | Maintains | Buy → Buy | — | $7.02 | $7.16 | +2.0% | +3.4% | +5.3% | +5.0% | +2.8% | +4.6% |
| May 28 | Barclays | Downgrade | Equal Weight → Underweight | — | $8.19 | $7.69 | -6.1% | -12.6% | -16.3% | -17.9% | -17.0% | -17.3% |
No insider trades available.
8-K
Unknown — 8-K Filing
Cortimelix raised capital through an offering to fund Varseta-M development and operations, diluting existing shareholders but providing runway for clinical progress and investor returns.
Mar 19
8-K
Unknown — 8-K Filing
CytomX announced a corporate action on March 16, 2026, but the incomplete filing lacks material details, making it impossible to assess impact on the stock until full disclosure is available.
Mar 16
Data updated apr 25, 2026 3:43am
· Source: massive.com